It's been a good year to own ASX tech stocks, particularly following the outsized rally that kicked off on 7 April.
As you may recall, tech shares, like most stocks, had been hammered in the lead up to 7 April as investors feared the potential fallout from US President Donald Trump's 'Liberation Day' global tariff campaign.
When that fallout turned out to be much smaller than the market had feared, ASX tech stocks led the rebound rally.
Below, we look at three of the Aussie tech companies spearheading that charge, and why top investment experts believe they're well-placed to keep outperforming.
Image source: Getty Images
How have these ASX tech stocks been tracking?
The S&P/ASX All Technology Index (ASX: XTX) is just about flat today, which sees the index up 8.7% in 2025. And it's gained 36.4% since the 7 April lows.
That's a pretty heady six-month gain.
But software-as-a-service (SaaS) provider Technology One Ltd (ASX: TNE) has delivered almost double those gains.
Shares in the ASX tech stock are up 1.4% today, changing hands for $39.61 each. This sees the Technology One share price up 29.4% year to date and up 61.2% since 7 April.
Life360 Inc (ASX: 360), which develops family-oriented software for location sharing, has enjoyed an even stronger run. Life360 shares are down 1.2% today, trading for $52.38 each.
Life360 shares remain up 131.7% in 2025 and they're up 212.6% since 7 April.
And shares in respiratory imaging technology company 4DMedical Ltd (ASX: 4DX) have surged even higher.
The ASX tech stock is down 3.0% today at $1.97 a share. But shares are up 310.4% in 2025 and have gained a blistering 688.0% since 7 April.
So, after these jaw-dropping gains, can these companies really keep pushing higher?
Expensive maybe, but growth outlooks intact
Alphinity Investment Management co-chief executive Andrew Martin acknowledged that valuations are increasing for many ASX tech stocks.
"We think it is fair to say you aren't going to find any cheap tech stocks on the ASX," he said (quoted by The Australian Financial Review).
But he still sees further growth avenues for Life360 shares.
"Life360 has an incredibly engaged user base, which is also very data rich," Martin said.
Martin is also bullish on the outlook for Technology One shares.
"The market undervalues the mid-teens, consistent growth the business can produce … without having to take material risks," Martin said.
And The Super Investor CEO Paul Nojin thinks that 4DMedical is well-positioned to mirror the success of ASX tech stock Pro Medicus Ltd (ASX: PME).
Pro Medicus shares have soared 860% over the last five years, giving the company a market cap north of $30 billion.
"I believe 4DMedical has all the attributes to be the next Pro Medicus, in terms of achieving very rapid growth, spectacular margins, and unprecedented valuations," Nojin said.
